Acne News and Research

Latest Acne News and Research

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

15 Sep 2009

Internet marketing program from AVVH

avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced today the launch of a major Internet marketing program.

14 Sep 2009

DSG’s eCaseLink EDC software used in Cipher's Phase 3 dermatology study

DSG Inc., an industry leader in clinical trial data collection and management, today announced that Cipher Pharmaceuticals (TSX:DND) is using electronic data capture (EDC) software and data management services from DSG. Cipher is using DSG’s eCaseLink™ for its Phase 3 dermatology study on its new compound for the treatment of severe acne.

14 Sep 2009

FDA accepts Merz Pharmaceuticals' premarket approval application for Belotero Balance

Merz Pharmaceuticals, LLC, a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Merz's premarket approval (PMA) application for Belotero(R) Balance.

11 Sep 2009

Solta Medical launches new Thermage CPT and Fraxel re:store Dual systems

Solta Medical, Inc. (Nasdaq: SLTM) is proud to celebrate the launch of the new Thermage CPT and Fraxel re:store Dual systems with the kick off of the illumiNATION tour (www.illumiNATIONtour.com). Starting September 14 and continuing through November, the illumiNATION tour is bringing the latest breakthroughs in Thermage(R) and Fraxel(R) systems directly to physicians in over 20 cities across the U.S. and 11 cities in Europe.

11 Sep 2009

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, continues to drive the global effort to ensure patients receive personalized cancer therapies. A total of 17 abstracts concerning Merck Serono oncology treatments will be presented at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), to be held in Berlin from 20-24 September 2009.

11 Sep 2009

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

NovaBay begins clinical studies for treating impetigo skin infection

NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo.

10 Sep 2009

Clinical trial reveals RENOVA topical treatment cream shows continuous improvement

In 2008, the global anti-aging skincare market approached $15 billion, with 32 percent of U.S. facial skincare product launches boasting anti-aging claims many over-the-counter products are claiming to achieve comparable benefits as prescription anti-aging treatments.

10 Sep 2009

Syneron Medical to merge with Candela Corporation

Syneron Medical Ltd. (NASDAQ:ELOS) and Candela Corporation (NASDAQ:CLZR) announced today that they have entered into a definitive agreement to combine the companies in an all stock transaction. This strategic combination, unanimously approved by the Boards of Directors of both companies, will create a global leader in medical aesthetic devices. The transaction is expected to be completed by year-end 2009.

9 Sep 2009

Nanoemulsion-based adjuvant increases immunity and cross protection against influenza

NanoBio Corp. announced today that data from a large ferret study indicates that its intranasal, nanoemulsion-based adjuvant elicits robust immunity and cross protection against influenza using 1/15th of the standard antigen dose, without evidence of toxicity or tolerability concerns.

9 Sep 2009

Valeant develops an acne drug with a low concentration of BPO combined with clindamycin

One of the most widely prescribed drugs for acne vulgaris is benzoyl peroxide (BPO). However, at concentrations of 5-10%, BPO has the potential for skin irritation and dryness leading to poor patient compliance. Increasingly, BPO is combined with clindamycin in a fixed combination where the efficacy effects of the two ingredients are synergistic.

8 Sep 2009

FDA undecided on safety guidelines for hydroquinone use

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the US market for physician-dispensed cosmeceutical pigment control products will experience considerable growth in sales over the next five years. MRG's US Markets for Physician-Dispensed Cosmeceuticals 2009 report finds, however, that product safety issues involving hydroquinone, the active ingredient in many pigment control products, have led the Food and Drug Administration (FDA) to second guess the use of the compound in such products.

8 Sep 2009

Giant Eagle offers generic prescription antibiotics for free at its in-store pharmacies

At a time when many families affected by a difficult economy are struggling with the costs of prescription medications, supermarket retailer Giant Eagle, Inc. is making ten broadly used generic prescription antibiotics in 46 common dosages available for free every day at all of its 210 in-store pharmacies.

4 Sep 2009

Results of Phase 2 rheumatoid arthritis clinical trial announced

Array BioPharma Inc. (Nasdaq: ARRY) announced its preliminary analysis of results from a study examining ARRY-162, a small molecule MEK inhibitor, in a 12-week Phase 2 clinical trial with 201 patients.

4 Sep 2009

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

Asset Purchase Agreement Signed for Marketed Prescription Products Desonate(R) and NeoBenz(R) Micro

3 Sep 2009

Antibiotic functioning as an off switch being developed for gene therapy of Parkinson's disease

A common antibiotic can function as an "off switch" for a gene therapy being developed for Parkinson's disease, according to University of Florida researchers writing online in advance of September's Molecular Therapy.

29 Aug 2009

Mylan Pharmaceuticals markets FDA approved first generic version of Sanofi Aventis' BenzaClin

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has begun to market 1% Clindamycin and 5% Benzoyl Peroxide Gel based on an agreement with licensing partner Dow Pharmaceutical Sciences, a subsidiary of Valeant Pharmaceuticals International. The preparation is the first generic version of Sanofi Aventis' BenzaClin(R) to be approved by the U.S. Food and Drug Administration (FDA).

27 Aug 2009

Research finds that people with psoriasis are less likely to react to looks of disgust by others

People with psoriasis - an often distressing dermatological condition that causes lesions and red scaly patches on the skin - are less likely to react to looks of disgust by others than people without the condition, new research has found.

From The University of Manchester 27 Aug 2009

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.

27 Aug 2009

Acne News and Research

Latest Acne News and Research

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

Internet marketing program from AVVH

DSG’s eCaseLink EDC software used in Cipher's Phase 3 dermatology study

FDA accepts Merz Pharmaceuticals' premarket approval application for Belotero Balance

Solta Medical launches new Thermage CPT and Fraxel re:store Dual systems

Abstracts on Merck Serono oncology treatments to be presented at ECCO and ESMO

Merck update on the status of telcagepant clinical development programs

NovaBay begins clinical studies for treating impetigo skin infection

Clinical trial reveals RENOVA topical treatment cream shows continuous improvement

Syneron Medical to merge with Candela Corporation

Nanoemulsion-based adjuvant increases immunity and cross protection against influenza

Valeant develops an acne drug with a low concentration of BPO combined with clindamycin

FDA undecided on safety guidelines for hydroquinone use

Giant Eagle offers generic prescription antibiotics for free at its in-store pharmacies

Results of Phase 2 rheumatoid arthritis clinical trial announced

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

Antibiotic functioning as an off switch being developed for gene therapy of Parkinson's disease

Mylan Pharmaceuticals markets FDA approved first generic version of Sanofi Aventis' BenzaClin

Research finds that people with psoriasis are less likely to react to looks of disgust by others

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Acne News and Research

Latest Acne News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in